DEFA14A: NovaBay Pharmaceuticals Engages Financial Advisor Amidst Dissolution Vote Uncertainty

NovaBay Pharmaceuticals engages Lucid Capital Markets to explore strategic alternatives, including a potential business combination, as it faces uncertainty regarding stockholder approval for the company's proposed liquidation and dissolution.

Summary

• NovaBay Pharmaceuticals has engaged Lucid Capital Markets to explore a potential business combination.
• This move comes as the company faces uncertainty regarding stockholder approval for its proposed liquidation and dissolution.
• Lucid will provide financial advisory services to explore strategic options such as mergers, reverse mergers, strategic partnerships, and licensing agreements.
• The engagement agreement lasts until the completion of a transaction, nine months from March 4, 2025, or upon written termination by either party.
• NovaBay will pay Lucid a $100,000 initial fee, potential monthly fees up to $250,000, an $800,000 transaction fee upon successful completion of a transaction, and a $300,000 fairness opinion fee.
• NovaBay plans to hold a special meeting on April 16, 2025, for stockholders to vote on the liquidation and dissolution proposal.
• A previous vote on January 30, 2025, saw approximately 49% of outstanding shares voting in favor, short of the required majority.
• The company intends to file a definitive proxy statement with the SEC regarding the special meeting.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is proactively exploring strategic alternatives, it is doing so due to uncertainty surrounding a critical vote and potential liquidation. The engagement of a financial advisor adds costs and doesn't guarantee a positive outcome.

Positives

• NovaBay is proactively exploring strategic alternatives to maximize stockholder value.
• The engagement of a financial advisor provides expertise in identifying and evaluating potential transactions.
• The agreement with Lucid includes a right of first refusal for Lucid to participate as a co-placement agent in any concurrent private placement equity financing by the Company contemplated along with a Potential Transaction.

Negatives

• Uncertainty remains regarding stockholder approval for the proposed liquidation and dissolution.
• The company incurred expenses related to a previously held special meeting where the dissolution proposal failed to pass.
• The company will incur significant fees to Lucid regardless of whether a transaction is completed.

Risks

• There is a risk that stockholders will not approve the liquidation and dissolution.
• The company may not be able to find a suitable strategic transaction.
• The company's financial condition could be negatively impacted by the costs associated with exploring strategic alternatives.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company is evaluating strategic alternatives while preparing for a special meeting to vote on the liquidation and dissolution proposal, aiming to ensure multiple paths forward regardless of the vote's outcome.

Management Comments

• 'Given our past voting challenges, we cannot be assured of obtaining stockholder approval for the Dissolution proposal at our upcoming Special Meeting,' said Justin Hall, NovaBay CEO.
• 'To that end, we have engaged a financial advisor to explore additional strategic options.'
• 'While we go through the process of holding another Special Meeting, we are also considering other strategic alternatives such as mergers, reverse mergers, strategic partnerships, and licensing and sub-licensing transactions to ensure we have multiple paths forward regardless of the outcome at the Special Meeting in April.'

Industry Context

The announcement reflects a trend among smaller pharmaceutical companies to explore strategic alternatives, including mergers and acquisitions, in response to challenges in securing funding and achieving profitability.

Comparison to Industry Standards

• The fees outlined in the engagement agreement with Lucid Capital Markets appear to be within the typical range for financial advisory services in similar transactions.
• Transaction fees for small-cap companies often range from 1% to 3% of the transaction value, and the $800,000 fee suggests a target transaction size in the $27 million to $80 million range.
• Fairness opinion fees of $300,000 are also standard for transactions of this scale.
• Comparable companies that have explored similar strategic alternatives include those facing challenges in commercializing their products or achieving sustained profitability.

Stakeholder Impact

• Shareholders face uncertainty regarding the future of the company and the potential for liquidation.
• Employees' jobs are at risk if the company liquidates.
• The company's customers and suppliers may be affected by the potential changes in the company's operations.

Next Steps

• File a definitive proxy statement with the SEC.
• Mail the definitive proxy statement and proxy card to stockholders.
• Hold a virtual Special Meeting on April 16, 2025.
• Continue evaluating strategic alternatives with Lucid Capital Markets.

Key Dates

Keywords

NovaBay Pharmaceuticals, Lucid Capital Markets, liquidation, dissolution, strategic alternatives, merger, reverse merger, financial advisor, proxy statement, stockholder vote